Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current Assets    
Cash and cash equivalents $ 28,918 $ 17,116
Prepaid expenses and other current assets 593 827
Total Current Assets 29,511 17,943
Property and equipment, net 607 872
Deposits and other assets 23 23
Total Assets 30,141 18,838
Current Liabilities:    
Accounts payable 1,034 2,020
Accrued expenses 919 1,526
Warrant liabilities 0 4,083
Accrued employee benefits 1,332 2,074
Deferred rent 99 90
Total Current Liabilities 3,384 9,793
Long term deferred rent 302 402
Total Liabilities 3,686 10,195
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 and zero shares authorized;120,000 issued and outstanding 12,296 12,053
Stockholders' Equity (Deficit):    
Common stock, $0.001 par value; 250,000,000 and 10,000,000 shares authorized, 15,484,411, issued and 15,482,083 outstanding and 3,673,342 issued and 3,671,014 outstanding 15 4
Additional paid-in capital 230,754 192,670
Accumulated deficit (219,461) (194,170)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit) 17,068 (1,496)
Non-controlling interest (2,909) (1,914)
Total Stockholders' Equity (Deficit) 14,159 (3,410)
Total Liabilities and Stockholders' Equity (Deficit) 30,141 18,838
Series B Preferred Stock [Member]    
Stockholders' Equity (Deficit):    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 15,723 issued and 9,161 outstanding 5,760 0
Total Stockholders' Equity (Deficit) $ 5,760 $ 0